Abstract
A new omega-3 fatty acid product, icosapent ethyl (Vascepa—Amarin), which contains primarily eicosapentaenoic acid (EPA, ≥ 96%) was approved by FDA for the management of patients with extremely high triglycerides. The capsules are indicated as an adjunct to diet to reduce triglyceride levels greater than or equal to 500 mg/dL in adults. The commercial launch of the product is slated for early in the first quarter of 2013.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
